Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 10, 2026

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

Interim PET in lymphoma: a step towards standardization

Michel Meignan

    European Journal of Nuclear Medicine and Molecular Imaging
    |July 24, 2010
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Last Updated: Jun 10, 2026

    Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
    07:52

    Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

    Published on: January 9, 2019

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline <sup>18</sup>F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation.

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2024
    Same author

    Validation of the ΔSUV<sub>max</sub> for Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial.

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2023
    Same author

    Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2022
    Same author

    <sup>18</sup>F-FDG PET Maximum-Intensity Projections and Artificial Intelligence: A Win-Win Combination to Easily Measure Prognostic Biomarkers in DLBCL Patients.

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2022
    Same author

    Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells.

    Haematologica·2022
    Same author

    High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline.

    Haematologica·2022